Animal Medication - Global Strategic Business Report

Global Animal Medication Market to Reach $45.9 Billion by 2030

The global market for Animal Medication estimated at US$32.1 Billion in the year 2022, is projected to reach a revised size of US$45.9 Billion by 2030, growing at a CAGR of 4.6% over the analysis period 2022-2030. Companion Animals, one of the segments analyzed in the report, is projected to record 4.8% CAGR and reach US$20.7 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Cattle Farm Animals segment is readjusted to a revised 3.4% CAGR for the next 8-year period.

The U.S. Market is Estimated at $8.7 Billion, While China is Forecast to Grow at 7.7% CAGR

The Animal Medication market in the U.S. is estimated at US$8.7 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$9.8 Billion by the year 2030 trailing a CAGR of 7.7% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.4% and 3.7% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3% CAGR.

Select Competitors (Total 63 Featured) -

• Bayer AG
• Boehringer Ingelheim International GmbH
• Ceva Santé Animale S.A.
• Dechra Pharmaceuticals Plc.
• Eli Lilly and Company
• Merck Animal Health
• Vetericyn Inc.
• Vétoquinol SA
• Virbac SA
• Zoetis Inc.

What's New?

• Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
• Global competitiveness and key competitor percentage market shares
• Market presence across multiple geographies - Strong/Active/Niche/Trivial
• Online interactive peer-to-peer collaborative bespoke updates
• Access to digital archives and Research Platform
• Complimentary updates for one year